Loading stock data…
Medtronic plc. (MDT)
$92.39-1.78 (-1.89%)
Market ClosedLast close Sep 8
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medtronic plc in the Healthcare sector is trading at $92.39 with a market capitalization of $106.5B. Wall Street consensus targets $104.76 (25 analysts), implying a +13.4% move over the next 12 months. The stock is currently 13% below its 52-week high of $106.33, remaining 4.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.81B↑ | $9.02B↑ | $8.96B↑ | $8.58B↓ | $8.93B |
| Gross Profit | $6.41B↑ | $5.76B↓ | $5.90B↑ | $5.58B↓ | $5.78B |
| Operating Income | $2.01B↑ | $1.60B↓ | $1.70B↑ | $1.52B↓ | $1.80B |
| Net Income | $1.24B↑ | $1.14B↓ | $1.37B↑ | $1.04B↓ | $1.06B |
Peer Comparison
JNJUNHPFE
Fundamentals
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Port...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$106.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.30
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.55%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.71%
Volume
Today's trading volume
8.09M
Recent News
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
4 Reasons to Buy Medtronic Stock Like There's No Tomorrow
The medical device maker is on the cusp of a multi-year recovery.